Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Peter van Vlasselaer | M | 64 |
Amphivena Therapeutics, Inc.
 Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | 5 years |
| peter vlasselaer | M | - |
Amphivena Therapeutics, Inc.
Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | 6 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Franklin Berger | M | 74 | 10 years | |
| John McLaughlin | M | 72 | 9 years | |
| John Orwin | M | 59 | 9 years | |
| Kirk D. Schumacher | M | - | 11 years | |
| Jean Liu | F | 55 | 9 years | |
| Christopher Boerner | M | 53 | 5 years | |
| Dennis Benjamin | M | - | 3 years | |
| Naomi Hunder | M | 54 | 7 years | |
| Leslie Aberman | F | - | 8 years | |
| Stanford Peng | M | 53 | 1 years | |
| Brandi Robinson | F | - | 2 years | |
| David Fontana | M | - | - | |
| Robert Lechleider | M | - | 4 years | |
| Elizabeth Bekiroglu | F | 54 | 5 years | |
| Eric Sievers | M | 60 | 9 years | |
| Florian Fischer | M | 56 |
Amphivena Therapeutics, Inc.
Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | - |
| Tina Albertson | M | 51 | 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 19 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Eric Feldman
- Personal Network
